FDA
-
-
-
-
-
-
-
Tarsus to Participate in Upcoming Investor Conference
-
-
-
-
-
-
-
Tarsus to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (A
-
-
-
-
-
-
-
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
-
-
-
-
-
-
-
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
-
-
-
-
-
-
-
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
-
-
-
-
-
-
-
Tarsus Pharmaceuticals (TARS) Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

